N-(2-Amino-phenyl)-4-(heteroarylmethyl)-benzamides as new histone deacetylase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 24, 2007, Pages 6729-6733

  Vaisburg, Arkadii ^a   Paquin, Isabelle ^a   Bernstein, Naomy ^a   Frechette, Sylvie ^a   Gaudette, Frederic ^a   Leit, Silvana ^a   Moradei, Oscar ^a   Raeppel, Stephane ^a   Zhou, Nancy ^a   Bouchain, Giliane ^a   Woo, Soon Hyung ^b   Jin, Zhiyun ^a   Gillespie, Jeff ^a   Wang, James ^a   Fournel, Marielle ^a   Yan, Pu Theresa ^a   Trachy Bourget, Marie Claude ^a   Robert, Marie France ^a   Lu, Aihua ^a   Yuk, Jimmy ^a   Rahil, Jubrail ^a   MacLeod, A Robert ^d   Besterman, Jeffrey M ^a   Li, Zuomei ^a   Delorme, Daniel ^c   more..

^a METHYLGENE INC   (Canada)

^b Auspex Pharmaceuticals   (United States)

^c Neurochem Inc   (Canada)

^d Takeda San Diego Inc   (United States)

Author keywords

Benzamides; Cancer cell proliferation; HDAC; Histone deacetylase inhibitors

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; AMINE; BENZAMIDE DERIVATIVE; BENZENE DERIVATIVE; CRA 024781; CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; LBH 589; MGCD 0103; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

AMINATION; ANIMALS; ANTHRANILIC ACIDS; BENZAMIDES; BINDING SITES; CELL LINE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; METHYLATION; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NIACIN; STRUCTURE-ACTIVITY RELATIONSHIP; UREA; VASODILATION;

MUS;

EID: 35848952499     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.10.050     Document Type: Article

References (30)

1. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Nat. Rev. Cancer (2001) 194
2. Hassig C.A., and Schreiber S.L. Curr. Opin. Chem. Biol. 1 (1997) 300
3. Kouzarides T. Curr. Opin. Genet. Dev. 9 (1999) 40
4. Drummond D.C., Noble G.K., Kirpotin D.B., Guo Z., Scott G.K., and Benz C.C. Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495
5. For recent reviews on HDAC inhibitors, see:. Moradei O., Maroun C.R., Paquin I., and Vaisburg A. Curr. Med. Chem. Anti-Cancer Agents 5 (2005) 529
6. Minucci S., and Pelicci G. Nat. Rev. Cancer 6 (2006) 38
7. Zhou, N.; Moradei, O.; Raeppel, S.; Leit, S.; Fréchette, S.; Gaudette, F.; Paquin, I.; Bouchain, G.; Bernstein, N.; Raeppel, F.; Saavedra, O.; Woo, S. H.; Vaisburg, A.; Wang, J.; Fournel, M.; Kalita, A.; Lu, A.; Trachy-Bourget, M.; Yan, P. T.; Liu, J.; Li, Z.; Rahil, G.; MacLeod, R.; Besterman, J.; Delorme, D. In Novel Benzamide Derivatives as Potent Histone Deacetylase (HDAC) Inhibitors: Synthesis and Antiproliferative Evaluation. Presented at the 232nd American Chemical Society National Meeting, San Francisco, CA, September 2006; Abstract MEDI 147.
8. Vaisburg, A. Discovery and Development of MGCD0103-An Orally Active HDAC Inhibitor in Human Clinical Trials. Presented at the XIXth International Symposium on Medicinal Chemistry, Istanbul, August 2006; Paper L57.
9. Patent Application WO 2004/092115.
10. Buggy J.J., Cao Z.A., Bass K.E., Verner E., Balasubramanian S., Liu L., Schultz B.E., Young P.R., and Dalrymple S.A. Mol. Cancer Ther. 5 (2006) 1309
11. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., La Tangue N.B., and Brown R. Mol. Cancer Ther. 2 (2003) 721
12. Patent Application WO 0230879A2, 2002.
13. Hansen M., Gimsing P., Rasmussen A., and Buhl Jensen P. J. Clin. Oncol. 23 (2005) 3137
14. Maiso P., et al. Cancer Res. 66 (2006) 5781
15. Giles F.J., et al. Blood 104 (2004) 499A
16. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 4592
17. Suzuki T., Ando T., Tsuchiya K., Fukasawa N., Saito A., Mariko Y., Yamashita T., and Nakanishi O. J. Med. Chem. 42 (1999) 3001
18. U.S. Patent 6174905, 2001.
19. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. J. Clin. Oncol. 23 (2005) 3912
20. Kim Y.B., Lee K.H., Sugita K., Yoshida M., and Horinouchi S. Oncogene 18 (1999) 2461
21. Review:. Meinke P.T., and Liberator P. Curr. Med. Chem. 8 (2000) 211
22. Patent Application US 6511990 B1, 2003.
23. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. J. Clin. Oncol. 23 (2005) 3923
24. Lavoie R., Bouchain G., Frechette S., Woo S.H., Abou-Khalil E., Leit S., Fournel M., Yan P.T., Trachy-Bourget M.-C., Beaulieu C., Li Z., Besterman J., and Delorme D. Bioorg. Med. Chem. Lett. 11 (2001) 2847
25. Bouchain G., Leit S., Frechette S., Abou-Khalil E., Lavoie R., Moradei O., Hyung Woo S.-H., Fournel M., Yan P.T., Trachy-Bourget M.-C., Beaulieu C., Zuomei Li., Robert M.-F., MacLeod A.R., Besterman J.M., and Delorme D. J. Med. Chem. 46 (2003) 820
26. Woo S.H., Frechette S., Abou-Khalil E., Bouchain G., Vaisburg A., Bernstein N., Moradei O., Leit S., Allan M., Fournel M., Trachy-Bourget M.-C., Li Z., Besterman J., and Delorme D. J. Med. Chem. 45 (2002) 2877
27. Vaisburg A., Bernstein N., Frechette S., Allan M., Abou-Khalil E., Leit S., Moradei O., Bouchain G., Wang J., Woo S.H., Fournel M., Yan P.T., Trachy-Bourget M.-C., Kalita A., Beaulieu C., Li Z., MacLeod R., Besterman J.M., and Delorme D. Bioorg. Med. Chem. Lett. 14 (2004) 283
28. Full experimental protocols for Schemes 1-4 are described in Patent Application WO 2003/024448, 2003.
29. Cachia P., Darby N., Eck Ch.R., and Money Th. J. Chem. Soc., Perkin Trans. 1 4 (1976) 359
30. em = 470 nm).